Cargando…

Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis

Detalles Bibliográficos
Autores principales:	Khan, Soheb, Funk, Connie A, Corado, Katya, Morris, Sheldon, Dube, Michael P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	ID Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300303/ https://www.ncbi.nlm.nih.gov/pubmed/30591921 http://dx.doi.org/10.1093/ofid/ofx149

Ejemplares similares

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya
por: Pintye, Jillian, et al.
Publicado: (2015)

2261. Phosphaturia in HIV-Exposed Uninfected Neonates Associated With Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy
por: Purswani, Murli, et al.
Publicado: (2018)

Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota
por: Dubé, Michael P., et al.
Publicado: (2018)

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
por: Rivera, Adovich, et al.
Publicado: (2023)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
por: Li, Chunmei, et al.
Publicado: (2022)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
por: Solomon, Marc M., et al.
Publicado: (2014)

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
por: Valin, Nadia, et al.
Publicado: (2016)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
por: Braithwaite, Kate, et al.
Publicado: (2021)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
por: Heron, Jack E., et al.
Publicado: (2023)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015)

Fanconi syndrome induced by the long-term use of tenofovir disoproxil fumarate: a case report and literature review
por: Li, Jiayi, et al.
Publicado: (2023)

Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization
por: Brunet, Laurence, et al.
Publicado: (2021)

Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients
por: Gupta, Samir K., et al.
Publicado: (2014)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)
por: Inciarte, Alexy, et al.
Publicado: (2023)

Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center
por: Marcus, Julia L, et al.
Publicado: (2021)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
por: Pontrelli, Giuseppe, et al.
Publicado: (2012)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
por: Kojima, Noah, et al.
Publicado: (2016)

Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
por: Hassan, Kowthar Salman, et al.
Publicado: (2019)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz()
por: Oster, Yonatan, et al.
Publicado: (2020)

Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people living with HIV
por: Hunt, Matthew, et al.
Publicado: (2022)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
por: Waters, Laura, et al.
Publicado: (2021)

Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
por: Phuphuakrat, Angsana, et al.
Publicado: (2022)

Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate
por: Ruone, Susan, et al.
Publicado: (2016)

Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis
por: Liegeon, Geoffroy, et al.
Publicado: (2020)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m0i3qljqh25hdbl7kvsfvat14j